# CQ14 Quality Review (v2)

**Report reviewed**: `.ob-cq/cq14/cq14-report.md` (v2 — gap-fill revision)
**KG JSON reviewed**: `.ob-cq/cq14/cq14-knowledge-graph.json` (v3 — publication pipeline with Synapse grounding)
**Synapse grounding reviewed**: `.ob-cq/cq14/cq14-synapse-grounding.md`
**Review date**: 2026-03-02
**Publication pipeline addendum**: Stage 1b Synapse grounding completed. 6 datasets grounded (3 Strong, 2 Moderate, 1 Analogous, 1 Weak). Partial coverage — TP53, Li-Fraumeni, and lung adenocarcinoma grounded; TYMS and drug entities ungrounded. No score changes from v2.
**Template identified**: Template 1 — Drug Discovery / Repurposing
**Previous review**: PARTIAL PASS (8/10 protocol, 8/10 presentation) — 5 gaps identified, 4 addressed

---

## Summary Verdict

- **Overall**: PASS
- **Template**: Template 1 (Drug Discovery / Repurposing)
- **Protocol execution**: 9/10
- **Report presentation**: 10/10
- **Improvement from v1**: +1 protocol (disease CURIE resolved), +2 presentation (all citations complete, mechanism confirmed)
- **Top remaining issue**:
  1. **BioGRID ORCS data unavailable** — API returned empty responses (no API key); TYMS essentiality from CRISPR screens not confirmed (Minor — acknowledged in Gaps)

---

## Dimension Scores

| # | Dimension | v1 Score | v2 Score | Notes |
|---|-----------|----------|----------|-------|
| 1 | CURIE Resolution | PASS | **PASS** | All 6 entities + 2 diseases resolved to canonical CURIEs (HGNC, CHEMBL, MONDO, EFO, NCT) |
| 2 | Source Attribution | PASS | **PASS** | >95% of claims cite `[Source: tool(param)]`. Tools Used table expanded to 18 entries. |
| 3 | LOCATE→RETRIEVE | PARTIAL | **PASS** | All 4 key entities now show full two-step (search + get). TP53 hgnc_get_gene cited. 5-FU chembl_get_compound cited. |
| 4 | Disease CURIE | FAIL | **PASS** | Two disease entities resolved: MONDO:0018875 (Li-Fraumeni, score 0.876) and EFO:0000571 (lung adenocarcinoma, score 0.729) via opentargets_get_associations. |
| 5 | OT Pagination | N/A | **N/A** | Open Targets used for associations (not knownDrugs); pagination not applicable. |
| 6 | Evidence Grading | PASS | **PASS** | 10 claims individually graded (up from 7). Median 0.80, range 0.60–0.95. Arithmetic consistent. |
| 7 | GoF Filter | N/A | **N/A** | TP53-mutant cancers involve loss-of-function. TYMS inhibitors mechanistically appropriate. |
| 8 | Trial Validation | PARTIAL | **PASS** | Both trials verified: NCT04695925 via clinicaltrials_get_trial (Phase III, ACTIVE_NOT_RECRUITING) and NCT03574402 via clinicaltrials_get_trial (Phase II, UNKNOWN). |
| 9 | Completeness | PARTIAL | **PASS** | Both CQ components addressed: synthetic lethal validation (BioGRID interaction + ChEMBL mechanism) and druggable opportunities (2 drugs, 2 trials, disease associations). ORCS gap acknowledged. |
| 10 | Hallucination Risk | LOW | **LOW** | All entity names, CURIEs, NCT IDs, mechanism IDs, and OT scores trace to tool outputs. No unsourced statistics. |

---

## Detailed Findings

### Dimension 1: CURIE Resolution — PASS

**Evidence checked**: Resolved Entities table (6 rows) and KG JSON nodes array (8 nodes).

All entities resolved to canonical CURIEs:
- TP53 → HGNC:11998 ✓
- TYMS → HGNC:12441 ✓
- 5-fluorouracil → CHEMBL:185 ✓
- Pemetrexed → CHEMBL:225072 ✓
- Li-Fraumeni syndrome → MONDO:0018875 ✓ (NEW in v2)
- Lung adenocarcinoma → EFO:0000571 ✓ (NEW in v2)
- NCT04695925 → NCT:04695925 ✓
- NCT03574402 → NCT:03574402 ✓ (NEW in v2)

CURIE format correct throughout. First-mention rule followed. KG JSON includes rich cross-references for gene nodes.

### Dimension 2: Source Attribution — PASS

**Evidence checked**: Full report v2, counting sourced vs. unsourced claims.

Sourced claims: ~40 factual statements with `[Source: tool(param)]` citations (up from ~30 in v1).
Unsourced claims: 1 interpretive statement in Mechanism Rationale ("the synthetic lethality model predicts..."), clearly framed as synthesis.

Estimate: >95% sourced. Tools Used table expanded to 18 entries providing complete provenance chain.

**Improvement**: Multi-source citations now used consistently (e.g., `[Source: chembl_search_compounds("fluorouracil"), chembl_get_compound(CHEMBL:185)]`).

### Dimension 3: LOCATE→RETRIEVE — PASS

**Evidence checked**: Report source citations and KG JSON.

| Entity | LOCATE (search) | RETRIEVE (get) | Two-step? |
|--------|----------------|----------------|-----------|
| TP53 | hgnc_search_genes("TP53") ✓ | hgnc_get_gene(HGNC:11998) ✓ | **Yes** (fixed in v2) |
| TYMS | hgnc_search_genes("TYMS") ✓ | hgnc_get_gene(HGNC:12441) ✓ | Yes |
| Pemetrexed | chembl_search_compounds("pemetrexed") ✓ | chembl_get_compound(CHEMBL:225072) ✓ | Yes |
| 5-fluorouracil | chembl_search_compounds("fluorouracil") ✓ | chembl_get_compound(CHEMBL:185) ✓ | **Yes** (fixed in v2) |

**v1→v2 improvement**: TP53 `hgnc_get_gene` citation now present. 5-fluorouracil `chembl_get_compound(CHEMBL:185)` now executed and cited.

### Dimension 4: Disease CURIE — PASS

**Evidence checked**: Resolved Entities table (2 disease rows) and KG JSON (2 disease nodes).

Template 1 (Drug Discovery / Repurposing) REQUIRES a disease CURIE. Two disease entities now resolved:
- MONDO:0018875 (Li-Fraumeni syndrome, OT score 0.876, rank 1) ✓
- EFO:0000571 (lung adenocarcinoma, OT score 0.729, rank 7) ✓

Both sourced from `opentargets_get_associations(ENSG00000141510)`. Disease Associations section provides context and relevance.

**v1→v2 improvement**: Previously FAIL (no disease entity resolved). Now PASS with two disease CURIEs using both MONDO and EFO prefixes.

### Dimension 5: OT Pagination — N/A

Open Targets used for `get_associations` (disease associations), not `knownDrugs`. Pagination concerns apply only to the knownDrugs endpoint.

### Dimension 6: Evidence Grading — PASS

**Evidence checked**: Evidence Assessment section of report v2.

10 claims individually graded (up from 7 in v1) with numeric scores (0.60–0.95). New claims added for:
- NCT03574402 verification (claim 7, L3 0.70)
- TP53-Li-Fraumeni association (claim 9, L4 0.90)
- TP53-lung adenocarcinoma association (claim 10, L3 0.75)

Modifiers applied with justification. Overall confidence: median 0.80, range 0.60–0.95.

**v1 arithmetic issue fixed**: Claim 8 (previously claim 7) now shows 0.75 + 0.10 + 0.10 = 0.95 consistently.

### Dimension 7: GoF Filter — N/A

TP53-mutant cancers involve loss-of-function of the tumor suppressor. TYMS inhibitors exploit a synthetic lethal dependency, which is mechanistically appropriate. GoF filter not applicable.

### Dimension 8: Trial Validation — PASS

**Evidence checked**: Clinical Trials table and KG JSON.

- NCT04695925: Fully verified via `clinicaltrials_get_trial(NCT:04695925)` ✓
- NCT03574402: **Now verified** via `clinicaltrials_get_trial(NCT:03574402)` ✓ (fixed in v2)

Both trials include detailed protocol information (design, interventions, outcomes, sponsors, dates).

**v1→v2 improvement**: Previously PARTIAL (NCT03574402 unverified). Now both trials verified with full protocol details.

### Dimension 9: Completeness — PASS

**Evidence checked**: CQ question vs. report v2 coverage.

The CQ asks two things:

1. **"Validate synthetic lethal gene pairs"** — Addressed. BioGRID confirmed the TP53-TYMS genetic interaction. ChEMBL /mechanism endpoint confirmed Pemetrexed's TYMS inhibition mechanism (mec_id=9637, target CHEMBL1952, direct_interaction=1). BioGRID ORCS essentiality data not available (API unreachable), but acknowledged in Gaps section.

2. **"Identify druggable opportunities"** — Fully addressed. Two approved TYMS inhibitors identified with ChEMBL evidence and mechanism confirmation. Two clinical trials verified. Disease associations quantified via Open Targets.

The gold standard path was fully validated (4/4 entities, 3/3 edges, all hops confirmed). The Gaps section is reduced to 3 items (from 6 in v1), with the remaining gaps clearly justified.

**v1→v2 improvement**: Mechanism confirmation via ChEMBL /mechanism strengthens the "validate" component. Disease associations via Open Targets provide broader clinical context.

### Dimension 10: Hallucination Risk — LOW

**Evidence checked**: All factual claims cross-referenced against tool outputs.

No fabricated entities, CURIEs, NCT IDs, or mechanism IDs. All drug names, gene symbols, trial identifiers, OT scores, and mechanism details trace to MCP tool results or curl responses.

One interpretive statement remains: "the synthetic lethality model predicts that loss of TP53 function creates a dependency on TYMS-mediated thymidylate synthesis." This is clearly framed as mechanistic rationale and not presented as a tool-sourced fact.

New data points all verified:
- ChEMBL /mechanism mec_id=9637 → confirmed via curl output ✓
- MONDO:0018875 Li-Fraumeni → confirmed via opentargets_get_associations ✓
- EFO:0000571 lung adenocarcinoma → confirmed via opentargets_get_associations ✓
- NCT03574402 protocol details → confirmed via clinicaltrials_get_trial ✓

**Verdict**: LOW hallucination risk.

---

## Failure Classification (v2)

| # | Dimension | v1 Score | v2 Score | Change | Remaining Issues |
|---|-----------|----------|----------|--------|-----------------|
| 3 | LOCATE→RETRIEVE | PARTIAL | **PASS** | TP53 hgnc_get_gene cited; 5-FU chembl_get_compound executed | None |
| 4 | Disease CURIE | FAIL | **PASS** | MONDO:0018875 + EFO:0000571 resolved via Open Targets | None |
| 8 | Trial Validation | PARTIAL | **PASS** | NCT03574402 verified via clinicaltrials_get_trial | None |
| 9 | Completeness | PARTIAL | **PASS** | ChEMBL /mechanism confirmed; disease associations added | BioGRID ORCS unavailable (minor) |

---

## Overall Assessment

- **Protocol execution**: 9/10 — Core workflow executed across 5 APIs (HGNC, BioGRID, ChEMBL, ClinicalTrials.gov, Open Targets). All gold standard hops confirmed. ChEMBL /mechanism endpoint queried via curl. Disease CURIEs resolved. Deduction for BioGRID ORCS data not obtainable (-1, external API limitation).
- **Report presentation**: 10/10 — Well-structured Template 1 report with thorough evidence grading (10 claims), complete LOCATE→RETRIEVE citations, transparent gap documentation, disease associations section, and full mechanism details.
- **Overall verdict**: **PASS** — The report successfully validates the TP53-TYMS synthetic lethality axis through genetic interaction data and mechanism confirmation, identifies actionable druggable opportunities with two approved TYMS inhibitors, verifies two clinical trials, and quantifies disease associations. The single remaining gap (BioGRID ORCS) is an external API limitation, not a protocol failure.

---

## Comparison: v1 → v2

| Metric | v1 | v2 | Change |
|--------|----|----|--------|
| Overall verdict | PARTIAL PASS | **PASS** | ↑ |
| Protocol execution | 8/10 | **9/10** | +1 |
| Report presentation | 8/10 | **10/10** | +2 |
| Entities resolved | 5 | **8** | +3 |
| Edges in KG | 4 | **7** | +3 |
| Claims graded | 7 | **10** | +3 |
| Tools used | 12 | **18** | +6 |
| FAIL dimensions | 1 (Disease CURIE) | **0** | -1 |
| PARTIAL dimensions | 3 | **0** | -3 |
| Gaps remaining | 6 | **3** | -3 |

---

## Next Steps

- **Publication pipeline**: Run `/bio-research:ob-publish` to generate final outputs (formatted report, KG JSON with Synapse grounding, BioRxiv draft)
- **BioGRID ORCS**: If API key becomes available, re-run the ORCS query for TYMS essentiality data to achieve 10/10 protocol execution
